CSL

ASX volatility continues amid global rate signals and GDP

5 clusters · 43 sources · last updated 5 days ago

Latest: ASX healthcare sector rebounds 42% from recent lows

The Australian Securities Exchange (ASX) has concluded its August earnings season, revealing a narrow recovery characterized by an 11.6 per cent rise in aggregate profits. While the healthcare sector demonstrated signifi

Gold prices fluctuate amid Fed signals and employment data

21 clusters · 449 sources · last updated 6 days ago

Latest: Gold prices drop following Federal Reserve Chair's Jackson Hole speech

Gold prices continued their downward trend in early September 2026, driven by intensifying fears of Federal Reserve interest rate hikes. Following the decline to approximately $4,430–$4,450 per ounce by September 7, new

US drug pricing and biotechnology policy initiatives

2 clusters · 31 sources · last updated 11 days ago

Latest: Trump expands drug pricing deals with nine pharmaceutical companies

The U.S. administration and the FDA have moved forward with initiatives involving biotechnology and drug pricing. Initially, the FDA and industry representatives released the Prescription Drug User Fee Act (PDUFA) VIII c

US administration prescription drug pricing policies

2 clusters · 3 sources · last updated 11 days ago

Latest: Trump administration targets drug and gas affordability

The Trump administration has focused on reducing costs for prescription drugs, with the White House claiming credit for a significant year-over-year decline in prices. While the administration attributes these shifts to

ASX 200 fluctuates amid gold surges and RBA rate speculation

21 clusters · 48 sources · last updated 15 days ago

Latest: Australian stock market recovers as tech and bank stocks rise

By late August 2026, the ASX 200 experienced continued volatility driven by shifts in commodity prices, US monetary policy, and domestic inflation data. On 19 August, the index rebounded from a multi-session losing strea